NEW YORK, Aug. 13, 2012 /PRNewswire/ -- Philosys announced today that it has received the CE Mark for the Gmate® SMART Blood Glucose Monitoring System. According to Jonathan Johnson, Director of Regulatory Affairs, "CE designation will allow Philosys to market the Gmate® SMART within the European Union,(EU), consisting of the 27 EU Member States. Moreover, the CE mark signifies that the product has been assessed before being placed on the market and meets European Union safety, health and environmental protection requirements." Gmate® SMART is the first of its kind blood glucose monitor to work with the iPhone, iPad and iPod devices. The CE Mark approval is an important milestone for Philosys in offering innovative technology to diabetics around the globe. Planning for the European market has been underway for more than a year and diabetic patients in the EU should be able to begin using the Gmate® SMART before the end of 2012.
"With the launch of the Gmate® SMART in Europe, Philosys provides the perfect solution to diabetics looking for new technology to help monitor blood glucose levels in an active, fast paced lifestyle," said Jennifer Kupar, Manager of Operations at Philosys. "As smart phone usage continues to increase in Europe, there is a growing demand for this breakthrough patent-pending technology that Philosys can deliver," Kupar continued.
As a next step, Philosys is pursuing global telecommunications contracts for the Gmate® SMART. Philosys is seeking to partner with major cell phone providers in a variety of markets to provide innovative health solutions to diabetic patients and health systems.
The Gmate® SMART is the smallest, most innovative glucose meter in the world. The patent pending technology of the Gmate® SMART uses the operating system of the smart phone and works by plugging the device into the headphone connector of the smart phone, and launching the companion app.
SOURCE Philosys, Inc.